Kristine Slam, MD, FACP, Central Ohio Surgical Associates, addresses the importance of involving patients in decisions regarding their goals for treatment, emphasizing that this involvement is critical to uncover what they value, as well as their short- and long-term goals for treatment.
"Part of the discussion we have with patients is, what are their values? It's really bringing the patient front and center and asking them about their short- and long-term goals, and their fears, because each patient chooses different surgery and different therapy based on that," noted Kristine Slam, MD, Central Ohio Surgical Associates, in an interview from our September 14 Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio.
Transcript
What roles do patient engagement and shared decision-making play in value-based care for breast cancer?
So patient decision-making and patient involvement in decision-making is critical. What I have found over my years is patients have different values and expectations. One of the things that comes to forefront with this is the application of breast radiation for, again, elderly lower-risk women. For years, we told patients a lumpectomy goes with radiation like peanut butter and jelly—you can't do one without the other. We have 2 very-long-term studies that clearly prove in low-risk elderly women, radiation does not make a patient live longer. It lowers the recurrence rate in the breast, but never eliminates it.
So part of the discussion we have with patients is, what are their values? Is their value and is their goal for their therapy living longer? Because if so, radiation is not going to help that. Is their goal to reduce their breast cancer risk as much as possible? If so, radiation might help. It's really bringing the patient front and center and asking them what their short-term and long term goals are, what their fears are, because each patient chooses different surgery and different therapy based on that.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Managed Care Reflections: A Q&A With David J. Shulkin, MD
July 7th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The July issue features a conversation with David J. Shulkin, MD, a physician and former secretary of the US Department of Veterans Affairs.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More